Frank H Gaertner

USPTO Granted Patents = 10 (Patent Applications = 2)

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 3.7

ph-index = 4

Forward Citations = 120(Granted Patents)

Company Filing History:

Research Corporation Technologies, Inc.

patents

Years Active: 1990-2018

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10041102 - [object Object] (2018-08-07),

2. 9458487 - [object Object] (2016-10-04),

3. 9453251 - [object Object] (2016-09-27),

4. 7338794 - Amended recombinant cells for the production and delivery of gamma interferon as an antiviral agent, adjuvant and vaccine accelerant (2008-03-04),

5. 5665600 - Pichia pastoris linear plasmids and DNA fragments thereof (1997-09-09),

6. 5468483 - Bacillus thuringiensis anti-giardia treatment (1995-11-21),

7. 5430137 - Probes for the identification of Bacillus thuringiensis endotoxin genes (1995-07-04),

8. 5281532 - Pseudomas hosts transformed with bacillus endotoxin genes (1994-01-25),

9. 5204237 - Universal and specific probes for Bacillus thuringiensis endotoxin genes (1993-04-20),

10. 4910016 - Novel Bacillus thuringiensis isolate (1990-03-20),

Title: Frank H. Gaertner: Innovator in Recombinant Protein Production

Introduction

Frank H. Gaertner is a notable inventor based in San Diego, CA. He has made significant contributions to the field of biotechnology, particularly in the production of recombinant mammalian proteins. With a total of 10 patents to his name, Gaertner's work has advanced the methods used in protein expression systems.

Latest Patents

Gaertner's latest patents focus on a process for improved production of recombinant mammalian proteins by expression in a Pseudomonad organism. This innovative process enhances the production of mammalian proteins, especially human or human-derived proteins, compared to existing expression systems. His inventions provide processes for the improved production of isolated mammalian proteins, particularly those derived from humans.

Career Highlights

Throughout his career, Frank H. Gaertner has worked with prominent companies in the biotechnology sector, including Mycogen Corporation and Pfenex Inc. His expertise in protein production has made him a valuable asset in these organizations.

Collaborations

Gaertner has collaborated with several professionals in his field, including Stacey Lynn Lee and Robert Shutter. These collaborations have contributed to the advancement of his research and innovations.

Conclusion

Frank H. Gaertner's contributions to the field of recombinant protein production have had a lasting impact on biotechnology. His innovative processes and collaborations continue to influence advancements in the industry.

This text is generated by artificial intelligence and may not be accurate.